

Discovery and Characterization of Small Molecule Inhibitors of Choline Acetyltransferase



Thesis submitted in partial fulfillment for the
Award of Degree of

Doctor of Philosophy

By

Anurag T.K. Baidya

**DEPARTMENT OF PHARMACEUTICAL ENGINEERING & TECHNOLOGY
INDIAN INSTITUTE OF TECHNOLOGY
(BANARAS HINDU UNIVERSITY)
VARANASI – 221005, INDIA**

Roll No: 20161505

2024

Dedicated to my family

CERTIFICATE

It is certified that the work contained in the thesis titled “Discovery and Characterization of Small Molecule Inhibitors of Choline Acetyltransferase” by Anurag TK Baidya has been carried out under my supervision and that this work has not been submitted elsewhere for a degree.

It is further certified that the student has fulfilled all the requirements of Course work, Comprehensive, Candidacy, SOTA and Pre-submission seminar.

Rajnish
14/5/25

Dr. Rajnish

Department of Pharmaceutical Engineering & Technology

Indian Institute of Technology (BHU), Varanasi-221005, U.P.

India

डा० रजनीश/Dr. Rajnish
सह आचार्य/Associate Professor
भैषजकीय अभियांत्रिकी एवं प्रौद्योगिकी विभाग/
Department of Pharmaceutical Engineering & Technology
भारतीय प्रौद्योगिकी संस्थान/Indian Institute of Technology
(काशी हिन्दू विश्वविद्यालय)/(Banaras Hindu University)
वाराणसी-२२१००५/Varanasi-221005

DECLARATION BY THE CANDIDATE

I, *Anurag TK Baidya*, certify that the work embodied in this Ph.D. thesis is my own bona fide work and carried out by me under the supervision of *Dr. Rajnish* from *January, 2021 to December, 2024* at the *Department of Pharmaceutical Engineering & Technology*, Indian Institute of Technology (B.H.U.), Varanasi. The matter embodied in this thesis has not been submitted for the award of any other degree/diploma. I declare that I have faithfully acknowledged and given credits to the research workers wherever their works have been cited in my work in this thesis. I further declare that I have not wilfully copied any other's work, paragraphs, text, data, results, etc., reported in journals, books, magazines, reports, dissertations, thesis, etc., or available at websites and have not included them in this Ph.D. thesis and have not cited as my own work.

Date: 14/05/2025

Anurag T.K. Baidya
(Anurag TK Baidya)

Place: IIT (BHU)

CERTIFICATE FROM THE SUPERVISOR

It is certified that the above statement made by the student is correct to the best of my/our knowledge.

Rajnish
14/5/25
(Dr. Rajnish)

Supervisor

डा० रजनीश/Dr. Rajnish
सह आचार्य/Associate Professor
वैद्यकीय अभियांत्रिकी एवं प्रौद्योगिकी विभाग/
Department of Pharmaceutical Engineering & Technology
भारतीय प्रौद्योगिकी संस्थान/Indian Institute of Technology
(काशी हिन्दू विश्वविद्यालय)/(Banaras Hindu University)
वाराणसी-221005/Varanasi-221005

Krishnamurthy
14/5/25
(Prof. Sairam Krishnamurthy)

Head of the Department

विभागाध्यक्ष/Head
वैद्यकीय अभियांत्रिकी एवं प्रौद्योगिकी विभाग/
Department of Pharmaceutical Engineering & Technology
भारतीय प्रौद्योगिकी संस्थान/INDIAN INSTITUTE OF TECHNOLOGY
(बनारस हिन्दू विश्वविद्यालय)/(BANARAS HINDU UNIVERSITY)
वाराणसी-221005/Varanasi-221005

COPYRIGHT TRANSFER CERTIFICATE

Title of the Thesis : "Discovery and Characterization of Small Molecule Inhibitors of Choline Acetyltransferase"

Name of the Student : Mr. Anurag TK Baidya

Copyright Transfer

The undersigned hereby assigns to the Indian Institute of Technology (Banaras Hindu University), Varanasi all rights under copyright that may exist in and for the above thesis submitted for the award of the "Doctor of Philosophy"

Date: 14/05/2025

Place: IIT (BHU)

Anurag T.K. Baidya
(Anurag TK Baidya)

Note: However, the author may reproduce or authorize others to reproduce material extracted verbatim from the thesis or derivative of the thesis for author's personal use provided that the source and the Institute's copyright notice are indicated.

ACKNOWLEDGEMENTS

At the outset, I am deeply humbled to pay tribute to the visionary Mahamana Pandit Madan Mohan Malaviya Ji, whose pioneering spirit led to the establishment of this distinguished institution. His legacy continues to inspire generations.

My heartfelt appreciation extends to the esteemed figures who have played a pivotal role in shaping my academic journey. My admiration knows no bounds for my mentor, Dr. Rajnish Kumar, whose relentless support, boundless motivation, unbridled enthusiasm, and unwavering encouragement have been instrumental in the successful execution of this research project.

I wish to express my profound gratitude to the Head of Department, Prof. K. Sairam, and former HODs, Prof. S. Hemalatha and Prof. Sushant Kumar Shrivastava, for their unwavering commitment in providing essential infrastructure and resources throughout my tenure.

I am also indebted to the erudite members of the Research and Project Evaluation Committee (RPEC), namely Dr. Shreyans Kumar Jain, and Dr. Sanjeev Kumar Mahto, for their invaluable insights and constructive guidance, which have significantly enhanced the quality of my doctoral research.

I extend my heartfelt appreciation to the entire faculty of the department, including Prof. B. Mishra, Prof. S. K. Singh, Prof. Sanjay Singh, Dr. A. K. Srivastava, Prof. A. Senthil Raja, Prof. M.S. Muthu, Dr. Ashok Kumar, Dr. A. N Sahu, Dr. S. K. Mishra, Dr. Ruchi Chawla, , Dr. Prasanta Kumar Nayak, Dr. S. K. Jain, Dr. Ashish Agarwal, Dr. Deepak, Dr. Dinesh, Dr. Jairam Meena, and Dr. Arun Khatri, whose unwavering support has been a guiding light during the course of my research.

I owe my gratitude to international collaborators, Prof. Taher-Darreh Shori and Davide Dante of the Karolinska Institutet, Stockholm, Sweden and Dr. Lisha Wang of the Karolinska Institutet, Solna, Sweden for their invaluable assistance in the biological evaluation of compounds. Prof. Bengt Långström and Prof. Hans Ågren of Uppsala University, Uppsala, Sweden for providing critical input during the preparation of the manuscript and design of the experiments.

In my scientific journey, I have been fortunate to have Dr. Vinod Tiwari as a beacon of guidance, offering steadfast support and encouragement not only during my in vivo studies but across all facets of my research.

Special recognition is due to my dedicated laboratory colleagues—Bhanuranjan Das, Bharti Chaudhary, Alen T Mathew, Rampa Rahul Salmon, Sourabh, Abhinetra, Abhinav, Akash, Prem, Alisha, Jatin, —for their indispensable contributions to my project.

I am deeply appreciative of the invaluable assistance and technical support provided by the non-teaching staff members of the department, whose efforts have been indispensable throughout my research tenure.

The indispensable support rendered by the Central Instrumentation Facilities of the Department, Institute, and the Department of Chemistry, BHU, alongside the Param Shivay supercomputer facility, has been a cornerstone in the realization of my research objectives.

My heartfelt thanks extend to my seniors Debadatta, Shreyasi, Himansu Rai, Akhilesh, Gauri sankar, Gaurav Singh, Sandeep Kumar, Rangan Mitra, Abhishes, Anurag, Venkatesh and Vishwanath, whose guidance and unwavering support have been instrumental.

I am truly grateful to my fellow Ph.D. scholars and juniors—Manjit, Asha, Aiswarya, Samarpita, Rahul Singh Rathore, Indurthi Harish, Naveen Dulla, Anoop, Deepak Chouhan, Somesh, Sunil Kumar, Abhinav, Ankit, Upesh, Subham Mandal, Nrayan Yadav, Hiral and Ravendra Kumar—for their stimulating discussions and the moments of respite they provided from the rigors of research. I also acknowledge the support of my M. Pharm juniors, Madhuri, Rohan and Nisha who aided me in my in-vivo experiments.

To my family, I owe boundless gratitude for their unwavering, unconditional, and affectionate support. My ever-curious, encouraging, and perpetually enthusiastic mother, Mrs. Shyamali Baidya, my father, Mr. Tarun Kumar Baidya and my sister, Ms. Arunima Baidya, have always been keenly interested in my endeavors and progress.

I extend my sincere thanks to the funding organizations, namely the Science & Engineering Research Board (SERB), the Ministry of Human Resource Development, and the Indian Institute of Technology (B.H.U.), whose financial support has made this work possible.

In conclusion, I bow with profound reverence and gratitude to Lord Shiva, Maa Gojabayani, and Jagannath Ji, whose blessings have bestowed upon me this extraordinary opportunity and empowered my mind to fulfill the tasks assigned.

Date:

Place:

(Anurag TK Baidya)

CONTENTS

Title	Page No.
Certificate	iii
Declaration by the Candidate	iv
Copyright Transfer Certificate	v
Acknowledgments	vi-vii
Contents	viii-xi
List of Figures	xii-xvi
List of Schemes	xvii
List of Tables	xviii
List of Abbreviations	xix-xx
PREFACE	xxi-xxiii
CHAPTER 1: Introduction and Literature Review	01-47
1.1. Alzheimer's Disease: A Progressive Neurodegenerative Disease	01-03
1.2. Prevalence of AD	03-05
1.3. Pathophysiology of AD	05-12
1.3.1. Cholinergic Hypothesis	06-08
1.3.2. Amyloid Cascade Hypothesis	08-10
1.3.3. Tau Hypothesis	10-12
1.4. Current Diagnostics for AD	12-14
1.5. Need of New and Effective Diagnostic Biomarker for AD	15-17
1.6. Choline Acetyltransferase as a Potential Biomarker	17-18
1.7. Structure of Choline Acetyltransferase	19-20
1.8. Previously Reported Choline Acetyltransferase Inhibitors	21-25
1.9. Computational Modeling in Drug Design	25-30
1.9.1. Molecular Docking	27-28
1.9.2. Molecular Dynamics	28
1.9.3. Artificial Intelligence in Drug Discovery	29-30
1.10. Piperidine: a versatile heterocyclic compound	31-40
1.10.1. Role of Piperidines in Neurodegenerative disease	31-36
1.10.2. Biological importance of Piperidine based molecules in other disease	36-40
1.11. References	40-47
CHAPTER 2: Research Envisaged	48-51
CHAPTER 3: Mechanistic insight into the inhibition of choline acetyltransferase by proton pump inhibitors	52-94
3.1. Introduction	52-54
3.2. Objectives	54-55
3.3. Results and Discussions	55-85
3.3.1. Molecular Docking Study	55-60
3.3.2. Molecular Dynamics Study	60-70
3.3.2.1. Principal Component Analysis	70-73
3.3.2.2. Free-Energy Landscape Analysis	73-76

	Title	Page No.
3.3.3	Residue Interaction Network (RIN) Analysis	76-78
3.3.4	Molecular Mechanics Poisson–Boltzmann Surface Area (MM-PBSA) Analysis	78-83
3.3.5	In Silico BBB Permeability Analysis	83-84
3.3.6	Molecular Docking Study	84-85
3.4.	Materials and Methods	86-90
3.4.1.	Molecular Docking Study	86-87
3.4.2.	Molecular Dynamics Simulation	87-88
3.4.3.	Residue Interaction Network Analysis	88
3.4.4.	MM-PBSA Calculation	88-89
3.4.5.	In-Silico BBB Predictions	89-90
3.5.	Conclusion	90-91
3.6	References	91-94
	CHAPTER 4: Design, Synthesis and Characterization of Piperidine Based Novel Derivatives for Choline Acetyltransferase Inhibitory Activity	95-143
4.1.	Introduction	95-96
4.2.	Objectives	96
4.3.	Results and Discussion	97-119
4.3.1.	Rationale of the design	97
4.3.2	Chemistry	97-101
4.3.3.	In vitro ChAT inhibition screening assay of the synthesized compounds A1 to A52	101-103
4.3.4.	ChAT inhibition kinetics analyses provided the inhibition constant and the mode of inhibition for A1	103-105
4.3.5.	In Vitro Cytotoxicity Assay	105-106
4.3.6.	Solubility and percentage purity analysis of the Hit Compound	106-107
4.3.7.	In Vivo studies of compound A1 in Sprague-Dawley rats	107
4.3.7.1.	A1 did not affect motor coordination post i.v. administration in rats in Rotarod test	107-108
4.3.7.2.	In-vivo pharmacokinetic study of compound A1	108-111
4.3.7.3.	In-vivo brain kinetic study of compound A1	111-113
4.3.8.	In Silico Molecular Docking Study	113-114
4.3.9.	Molecular Dynamics Simulation Study	114-119
4.4.	Materials and Methods	119-141
4.4.1.	Chemistry	119-134
4.4.1.1.	General procedure for the synthesis of Boc protected isonipecotic acid (Intermediate-1)	120
4.4.1.2.	General procedure for the synthesis of Piperidine Based amide substituted compounds (A1 to A52)	120-134
4.4.2.	In Vitro Assay	134-137
4.4.2.1.	Production and purification of recombinant human ChAT protein	134
4.4.2.2.	In vitro fluorometric ChAT activity inhibition assay	134-135

	Title	Page No.
4.4.2.3.	In vitro colorimetric AChE and BChE activity inhibition assay	135-136
4.4.2.4.	Enzyme inhibition kinetics for determination of K_i , IC_{50} , and mode of action of hits compounds	136-137
4.4.2.5.	In Vitro Cytotoxicity Assay	137
4.4.3.	In Vivo Studies of Compound A1 in Sprague Dawley rats	138-139
4.4.3.1.	Experimental animals	138
4.4.3.2.	Motor coordination	138
4.4.3.3.	In vivo pharmacokinetics	138-139
4.4.3.4.	In vivo brain kinetics	139
4.4.4.	Solubility and percentage purity assay	139-140
4.4.5.	Computational Details	139-141
4.4.5.1.	Molecular Docking	140
4.4.5.2.	Molecular Dynamics	141
4.5.	Conclusion	142
4.6.	References	142-143
	CHAPTER 5: Discovery and characterization of novel pyridine and furan substituted ligands of choline acetyltransferase	144-184
5.1.	Introduction	144-145
5.2.	Objectives	146
5.3.	Results and Discussion	146-172
5.3.1.	Structure based virtual screening identified several potential ChAT inhibitors	146-151
5.3.2.	Selection of compound V6 and V15 with in vitro ChAT inhibition screening assay	151-154
5.3.2.1.	ChAT inhibition kinetics analyses provided the inhibition constant and the mode of inhibition for V6 and V15	154-159
5.3.2.2.	V6 and V15 did not exhibit cell toxicity at as high as 50 μ M concentration	159-160
5.3.3.	Hit compounds V6 and V15 interacts well with the binding pocket of ChAT	160-163
5.3.4.	Molecular Dynamics Simulation	163-168
5.3.5.	Similarity Index Analysis	168-170
5.3.6.	Solubility study	170-172
5.4.	Materials and Methods	172-180
5.4.1.	Virtual screening protocol	172-174
5.4.1.1.	Protein structure preparation	172-173
5.4.1.2.	VitasM screening library acquisition and preparation	173
5.4.1.3.	Virtual Screening	173
5.4.1.4.	Post screening rescoring and MM/GBSA analysis	174
5.4.2.	Production and purification of recombinant human ChAT protein	174
5.4.2.1.	In vitro fluorometric ChAT activity inhibition assay	174-175
5.4.2.2.	In vitro colorimetric AChE and BChE activity inhibition	175-176

	Title	Page No.
	assay	
5.4.2.3.	Enzyme inhibition kinetics for determination of K_i , IC_{50} , and mode of action of hits compounds	176-177
5.4.2.4.	Cell viability assay	177-178
5.4.3.	Molecular Dynamics simulation	178-179
5.4.4.	Similarity Index Analysis	179
5.4.5.	Solubility and parentage purity assay	179-180
5.5.	Conclusion	180-181
5.6.	References	182-184
	CHAPTER 6: AI-Enabled Ultra-large Virtual Screening Identifies Potential Inhibitors of Choline Acetyltransferase for Theranostic Purposes	185-226
6.1.	Introduction	184-186
6.2.	Objective	186
6.3.	Results and discussion	186-217
6.3.1.	AI-Enabled Virtual Screening Using Deep Docking	186-189
6.3.2.	Molecular Mechanics Poisson–Boltzmann Surface Area (MMPBSA) Rescoring of the Docking Poses	189-202
6.3.3.	In Silico Pharmacokinetic Study	202-203
6.3.4.	Molecular Dynamics Simulation	203-213
6.3.5.	Molecular Mechanics Poisson–Boltzmann Surface Area Analysis	213-216
6.3.6.	Similarity Index Analysis	216-217
6.4.	Material and methods	218-223
6.4.1.	Deep Docking Protocol	218-220
6.4.1.1.	Preparation of the Ligand Database	218
6.4.1.2.	Molecular Docking	218-219
6.4.1.3.	Deep Docking Iterations	219-220
6.4.2.	MMPBSA Rescoring of the Docking Poses	220
6.4.3.	In Silico Pharmacokinetic Study	221
6.4.4.	Molecular Dynamics Simulation	221
6.4.4.1.	H-Bond Occupancy Analysis	221
6.4.4.2.	Molecular Mechanics Poisson–Boltzmann and Surface Area (MMPBSA) Analysis	221-222
6.4.4.	Similarity Index Analysis	222-223
6.5.	Conclusion	223-225
6.6.	References	225-226
	CHAPTER 7: Summary & Conclusion	227-232
	Annexure I: List of NMR, HRMS, HPLC Data for Chapter 4	233-292
	Annexure II: List of Publication	293-298

LIST OF FIGURES

Figure no.	Legend	Page no.
CHAPTER 1: Introduction and Literature Review		
1.1	Alzheimer's Disease Continuum	2
1.2	Alzheimer's Disease risk in numbers	4
1.3	The Cholinergic hypothesis in AD	8
1.4	The amyloid beta cascade	10
1.5	Tau hypothesis in AD	11
1.6	The AD continuum with corresponding pathological changes, biomarkers and clinical diagnosis	17
1.7	Structures of ligand bound human choline acetyltransferase (PDB ID = 2FY3)	20
1.8	Role of Artificial Intelligence (AI) in drug discovery	30
CHAPTER 3: Mechanistic insight into the inhibition of choline acetyltransferase by proton pump inhibitors		
3.1	PPIs Benzimidazole moiety is shown in brown circle (4-Azabenzimidazole for the Tenatoprazole) and the pyridine ring is shown in green circle.	52
3.2	3D re-docking pose of choline in comparison to the crystal structure pose	56
3.3	3D-docking poses for α -NETA as the classical ChAT inhibitor, which is used as a reference compound for comparison in the study	56
3.4	Comparison of the selected 3D-docking poses for stereoisomers of Omeprazole, Rabeprazole, and Tenatoprazole with ChAT	57
3.5	3D docking pose of PPIs with ChAT	58
3.6	RMSD analysis of the 200 ns trajectory obtained from molecular dynamics simulations	61
3.7	RMSF analysis of ChAT protein as a function of individual amino acid of the 200 ns trajectory obtained from molecular dynamics simulation	63
3.8	RMSF analysis was performed for the α -NETA and PPIs as a function of individual atom of the 200 ns trajectory obtained from molecular dynamics simulation in order to measure the average deviation of the atoms over the time from a reference position	64
3.9	RoG analysis was performed for the α -NETA and PPIs complexed with ChAT	65
3.10	Hydrogen Bond Number (HBN) analysis of ChAT's ligands during 200 ns molecular dynamics simulation	67
3.11	Solvent Accessible Surface Area (SASA) analysis of the ChAT protein and ChAT-PPI complexes	69
3.12	SASA of the ChAT protein and ChAT-PPI complex	70
3.13	The eigenvalues of the first 10 principal components of the simulated	71

Figure no.	Legend	Page no.
	system for the ChAT-ligand complexes	
3.14	Representation of the eigenvalues of the first 10 principal components for all the ChAT-PPI complex simulated system	72
3.15	The 2D projection of the first two principal components for the ChAT-ligand complex system	73
3.16	The 2D and 3D free energy landscape diagram as a function of RMSD and Rog as the two coordinates that depict the folding of ChAT- during its interaction with α NETA versus the stereoisomers of PPIs	74
3.17	The 2D and 3D free energy landscape diagram as a function of RMSD and Rog as the two coordinates that depict the folding of ChAT- during its interaction with α NETA versus the stereoisomers of PPIs	75
3..18	The Residue Interaction Network Analysis for α -NETA versus the stereoisomers of Omeprazole with ChAT	77
3.19	Residue Interaction Network (RIN) Analysis of PPIs with ChAT	78
3.20	Violin plot for the in silico calculated ΔG binding free energies, (kcal/mol) by MM-PBSA	80
3.21	In silico calculated Binding Free Energy (Kcal/mol) ΔG by MM-PBSA	82
3.22	In silico calculated Binding Free Energy (Kcal/mol) ΔG by MM-PBSA	83
3.23	Comparison of the selected 2D-docking poses for the stereoisomers of N-methyl Tenatoprazole with ChAT	85
3.24	3D comparison diagram of the binding mode of Tenatoprazole vs N-methyl Tenatoprazole in the ChAT binding tunnel	85
CHAPTER 4: Design, Synthesis and Characterization of Piperidine Based Novel Derivatives for Choline Acetyltransferase Inhibitory Activity		
4.1	Rationale of the synthetic scheme	97
4.2	Screening of synthesized compounds for ChAT, AChE and BuChE enzymes inhibition	102
4.3	ChAT Inhibition Kinetic for compound A1	104
4.4	Cellular toxicity analyses for A1 using the human neuroblastoma cell line, SH-SY5Y cells. The analyses were done using MTT cell viability test. The cells were exposed for 24 hours to the 10 and 50 μ M final concentrations of the compounds. Data are expressed as % mean values \pm SD of 6 readings. Viability of the vehicle treated control cells were considered as 100%.	106
4.5	Morphological changes of SH-SY5Y cells as observed under an inverted light microscope (Nikon ECLIPSE TE300, 20 \times magnification).	106
4.6	Solubility and percentage purity of A1 : HPLC: Agilent 2004, Column Specification Poroshell 123, EC C18 4 μ m, 4.6*150mm, sample volume for each injection was 20 μ l. A) HPLC calibration curve for A1 using 6 times serial dilutions of 100 μ M, 50 μ M, 25 μ M, 12.5 μ M, 6.25 μ M and	107

Figure no.	Legend	Page no.
	3.125 μ M; B) HPLC chromatogram of compound A1, where gradient and isocratic method was used, solvent system used Acetonitrile = 0-70 %: Water = 100-30 % for initial 2 minutes and continued for the next 9 minutes, Flow rate was set to 0.4 ml/min, Absorbance was recorded at 250nm	
4.7	A1 did not affect motor coordination in SD rats. A1 administration in normal healthy SD rats showed no sign of motor incoordination in the rotarod test. Data were expressed as Mean \pm SEM and analyzed by two-way ANOVA (Tukey's multiple comparisons) (n=6). Red indicates the vehicle group and green indicates the test group administered A1. A1 doses (10mg/kg i.v.).	108
4.8	Concentration in plasma for A1 obtained from in vivo pharmacokinetic study. A) A1 administered at 1 mg/kg i.v.; B) A1 administered at 5 mg/kg i.v.; C) A1 administered at 10 mg/kg i.v. The result obtained was the average of the three readings taken and the error bars are shown as the Standard deviation (SD).	110
4.9	Concentration in brain for A1 obtained from in vivo brain kinetic study. A1 administered at 10 mg/kg i.v. The result obtained was the average of the three readings taken and the error bars are shown as the Standard deviation (SD).	112
4.10	2D docking interaction diagram. A) For compound A1; B) For standard α -NETA.	114
4.11	Comparative analysis for the 200 ns simulated MD trajectories of ChAT_ α -NETA as reference and ChAT_A1 complex	117
4.12	PCA and FEL analysis of the obtained trajectories	119
CHAPTER 5: Discovery and characterization of novel pyridine and furan substituted ligands of choline acetyltransferase		
5.1	Overview of the structure-based virtual screening protocol for the 1.4 million VitasM compound library using VinaMPI for potential hits identification against ChAT	148
5.2	Screening of 46 virtual hit compounds for ChAT, AChE and BuChE enzymes inhibition	151
5.3	ChAT Inhibition Kinetic for compound V6	156
5.4	ChAT Inhibition Kinetic for compound V15	157
5.5	Cellular toxicity analyses for V6 and V15 using the human neuroblastoma cell line, SH-SY5Y cells. The analyses were done using MTT cell viability test. The cells were exposed for 24 hours to the 10 and 50 μ M final concentrations of the compounds. Data are expressed as % mean values \pm SD of 6 readings. Viability of the vehicle treated control cells were considered as 100%.	159
5.6	Morphological changes of SH-SY5Y cells as observed under an inverted light microscope (Nikon ECLIPSE TE300, 20 \times	160

Figure no.	Legend	Page no.
	magnification).	
5.7	3D and 2D docking interaction diagram for the top performing compounds V6 and V15. STK161404 and STK306932 are the catalogue numbers of these two compounds in the VitasM library	163
5.8	Comparative analysis for the 200 ns simulated MD trajectories	165
5.9	PCA and FEL analysis of the simulated systems	167
5.10	Histograms of structural similarity shown as Tanimoto coefficient of the hit compounds STK161404 (V6) and STK306932 (V15) against reported human ChAT inhibitors. Active compounds against human ChAT were obtained from ChEMBL (ID: ChEMBL4039) and compared to the two identified hit compounds using Morgan, AtomPair and MACCS fingerprints using RDKit	170
5.11	HPLC calibration curve for the compounds using serial dilutions of 200 μ M, 100 μ M, 50 μ M, 25 μ M, 12.5 μ M, 6.25 μ M and 3.125 μ M A) V6, R2 value was 0.9932; B) V15, R2 value was 0.9982	171
5.12	Single injection HPLC chromatogram of hit compounds for percentage purity calculation. A) V6, Solvent system used Acetonitrile = 90%: Water = 10%, Flow rate was set to 0.4 ml/min, Absorbance was recorded at 382 nm; B) V15 Solvent system used Acetonitrile = 75%: Water = 25%, Flow rate was set to 0.4 ml/min, Absorbance was recorded at 250 nm.	172
CHAPTER 6: AI-Enabled Ultra-large Virtual Screening Identifies Potential Inhibitors of Choline Acetyltransferase for Theranostic Purposes		
6.1	Overall workflow diagram of the Deep Docking based virtual screening protocol.	187
6.2	Receiver Operating Characteristic (ROC) curve for the three iterations, colour coded as iteration 1 (blue), iteration 2 (orange) and iteration 3 (green); TPR – True Positive Rate, FPR – False Positive Rate, AUC – Area Under the Curve.	189
6.3	Top five novel hit compounds identified as potential ChAT inhibitors	203
6.4	Molecular dynamics simulation analyses for the 200 ns simulation trajectory	205
6.5	Molecular dynamics simulation analyses for the 200 ns simulation trajectory	207
6.6	Per-residue hydrogen-bond occupancy analysis	210
6.7	Eigenvalue calculation for the first 10 principal components	211
6.8	The first two PCs were used to make the 2D projections of the simulated systems	212
6.9	FEL plot 2D and 3D representations	213
6.10	In silico Binding Free Energy (Kcal/mol) calculation (Δ G) by MM-PBSA	214

Figure no.	Legend	Page no.
6.11	Violin plot for the MM/PBSA binding free energy (ΔG) (kcal/mol)	216
6.12	A) Previously reported ChAT inhibitors; B) Tanimoto Similarity Heatmap	217
CHAPTER 7: Summary & Conclusion		
7.1	Overall summary of the research work carried out in the thesis	232

LIST OF SCHEMES

Scheme no.	Title	Page no.
4.1.	Synthesis of the starting material intermediate-1 in first step.	98
4.2	Synthesis of the piperidine based amide derivatives, compounds A1 to A52.	98

LIST OF TABLES

Table no.	Title	Page no.
1.1.	List of NVP derivatives with selective ChAT inhibition	21
1.2.	List of stiblazole derivatives with selective ChAT inhibition	22
3.1.	Molecular docking binding GScore of top three binding pose of PPIs with ChAT protein	58-59
3.2.	MM-PBSA binding free energy (ΔG) calculations for PPIs with ChAT	79
3.3.	Predicted in-silico BBB permeability	84
4.1	Structure of the synthesized piperidine based derivatives A1 to A52	98-101
4.2	The K_m and V_{max} values for compound A1 at different concentrations, obtained from the ChAT inhibition kinetic analysis performed using GraphPad Prism 7	104
4.3	In-vivo pharmacokinetic animal distribution	109
4.4	In-vivo pharmacokinetic parameter estimation	111
4.5	In-vivo brain kinetic parameter estimation	112-113
5.1	List of top 46 compounds along with their VitasM codes and SMILES	149-151
5.2	In vitro inhibitory screening data for the 46 top virtual hits from VitasM library	152-154
5.3	The K_m and V_{max} values for compound V6 and V15 at different concentrations, obtained from the ChAT inhibition kinetic analysis performed using GraphPad Prism 7	158-159
5.4	Comparison of the docking scores from virtual screening and re-docking along with the MM/GBSA scores for the top 46 hits	161-162
6.1	Model test parameters for the Deep Docking iterations	188
6.2	Model train and validation parameters for the Deep Docking iterations	188
6.3	Top scoring hits obtained from the Deep Docking	190-202
6.4	MMPBSA Binding Free Energy (ΔG) Calculations for the top five hits with ChAT protein	215

LIST OF ABBREVIATIONS

Abbreviation	Full form
AD	Alzheimer's Disease
WHO	World Health Organization
GBDS	Global Burden of Disease Study
SDI	Socio-Demographic Index
FAD	Familial AD
APP	Amyloid Precursor Protein
PS1	Presenilin 1
PS2	Presenilin 2
SAD	Sporadic AD
GWAS	Genome-Wide Association Studies
A β	Amyloid Beta
NFTs	Neuro Fibrillary Tangles
ACh	Acetylcholine
BFCNs	Basic Forebrain Cholinergic Neurons
NGF	Nerve Growth Factor
NACHR	Nicotinic Acetylcholine Receptors
AChE	Acetylcholinesterase
CNS	Central Nervous System
CTFs	α - or β -C Terminal Fragments
C99	C-terminal fragment of APP
AICD	APP Intracellular Domain
PHFs	Paired Helical Filaments
SFs	Straight Filaments
PET	Positron Emission Tomography
MRI	Magnetic Resonance Imaging
CSF	Cerebrospinal Fluid
MCI	Mild Cognitive Impairment
CI	Confidence Interval
FDG	Fluorodeoxyglucose
FDA	Food and Drug Administration
MAO-B	Monoamine Oxidase B
BBB	Blood Brain Barrier
acetyl-CoA	Acetyl-Coenzyme A
VACHT	Vesicular Acetylcholine Transporter
PDB	Protein Data Bank
NVP	Naphthylvinylpyridine
CADD	Computer Aided Drug Design
LBDD	Ligand-Based Drug Design
SBDD	Structure-Based Drug Design
MD	Molecular Dynamics
QSAR	Quantitative-Structure-Activity Relationship

Abbreviation	Full form
ADMET	Absorption, Distribution, Metabolism, Excretion, Toxicity
PK	Pharmacokinetic
AI	Artificial Intelligence
MTDLs	Multi-Target Directed Ligands
PAS	Peripheral Anionic Site
CAS	Catalytic Anionic Site
MIC	Minimum Inhibitory Concentration
PPIs	Proton Pump Inhibitors
BChE	Butyrylcholinesterase
ChAT	Choline Acetyltransferase
α -NETA	2-(α -naphthoyl) ethyltrimethylammonium iodide
RMSD	Root Mean Square Deviation
RMSF	Root Mean Square Fluctuation
RoG	Radius of Gyration
HBN	Hydrogen Bond Number
HBD	Hydrogen Bond Distance
PCA	Principal Component Analysis
FEL	Free-Energy Landscape
SASA	Solvent Accessible Surface Area
RIN	Residue Interaction Network
MM-PBSA	Molecular Mechanics Poisson–Boltzmann Surface Area
ΔG	Binding free energy
XP	Extra Precision
i.v.	Intra Venous
P.O.	Per Oral
HPLC	High Performance Liquid Chromatography
SD	Standard Deviation
HRMS	High-Resolution Mass Spectra
ALS	Amyotrophic Lateral Sclerosis
LBD	Lewy Body Disorder
MM/GBSA	Molecular Mechanics General Born Surface Area
K_m	Michaelis-Menten constant
V_{max}	Maximal Velocity
DMEM	Dulbecco's Modified Eagle's medium
FBS	Fetal Bovine Serum
DNN	Deep Neural Network
AI-DD	AI-assisted deep docking
ROC	Receiver Operating Characteristic
PC	Principal component
PDF	Probability density function

PREFACE

Alzheimer's Disease (AD) is one of the most predominant neurodegenerative diseases which accounts for 60 to 80 % cases of dementia, affecting the cerebral cortex and hippocampus of the brain characterized by cognitive decline, memory impairment, and behavioral alterations. A common denominator in such neurodegenerative diseases is the degeneration of the neuronal cholinergic system. Such neurodegenerative disease alone constitutes major challenges and tremendous unmet needs, in term of effective tools for clinical and/or research purposes. This is perhaps one of the reasons why despite the intensive search for the past half century only symptomatic treatments are currently available. Nonetheless, AD is a complex multifactorial disease, making it highly challenging to find a cure.

Cholinergic hypotheses in AD, is linked with the decline in the key cholinergic neurotransmitter, acetylcholine. Choline Acetyltransferase (ChAT) is the enzyme responsible for the biosynthesis of acetylcholine and the maintenance of ChAT expressions is essential for proper neuronal function and overall health of the brain and the body, and disruption in its expression or function can have detrimental effects on both mental abilities and neurotransmitter balance and motor controls. Thereby, it is one of the potential targets for development of biomarkers for monitoring the health of the cholinergic neurons in the central and peripheral nervous system for early-stage diagnosis. In addition, detecting early bio-signature changes of AD should help to halt the progression by suitable therapeutics.

My journey through the corridors of academia has led me to embark on a profound exploration of novel Piperidine based derivatives as potential ChAT inhibitors. The pages that follow document the culmination of years of rigorous research, investigation, and discovery. The work encapsulated herein is divided into four comprehensive studies, each a distinctive facet of the overarching endeavor to unlock the mysteries of AD and advance diagnostic and theranostic interventions.

Study I (**Chapter 3**) Unravels the crucial binding mode mechanism of the proton pump inhibitors to the ChAT binding tunnel, by employing a series of computational tools, namely molecular docking and classical molecular dynamics, followed by the calculation of binding free energies using MMPBSA. Additionally, it was observed that the pyridine ring of the PPI's predominantly interacts with the catalytic residue HIS324. As a major factor for the onset of Alzheimer's disease is linked to cholinergic dysfunction, our present findings give clear insight into the PPI's interaction with ChAT.

In Study II (**Chapter 4**), we embark on to explore the novel piperidine scaffold of the previously identified hit compound B4 from our lab with an objective to simplify the structure, thus, here we synthesized and characterized fifty-two piperidine-based amide derivatives of high purity. These compounds underwent rigorous evaluation for their ability to inhibit ChAT, and also evaluated for its selectivity by screening them against two off-targets AChE and BuChE. Compound A1 emerges as a promising lead, distinguished by its potent and selective inhibition of ChAT in vitro along with good solubility. In vivo pharmacokinetic and brain kinetic studies in rat indicated optimum pharmacokinetic parameters along with good brain permeability. Molecular docking and dynamics simulations reinforce the favorable interaction of A1 with ChAT binding tunnel indicating its interaction with the catalytic residue HIS324.

Study III (**Chapter 5**) We aimed to explore a large chemical space in search for novel scaffolds as potential ChAT inhibitors. Here, we have successfully utilised structure-based virtual screening approach to screen a VITAS-M small molecule library containing ~1.4 million compounds by using a structure-based virtual screen protocol based on MPI-Vina. Identifying 46 top performing hits displaying prominent interaction with the catalytic residue HIS324. The compounds were procured and were then subjected to rigorous in vitro characterization which led to the identification of two novel, selective and potent ChAT inhibitors V6 and V15, having good aqueous solubility and no toxicity. Molecular docking and dynamics simulations revealed

the intricate interaction dynamics for V6 and V15 with ChAT binding pocket. the Tanimoto similarity analysis indicated the novelty and structural diversity of the hits.

Study IV (**Chapter 6**) employs an innovative AI-assisted structure-based virtual screening tool, Deep Docking, to explore an ultra-large library of 1.3 billion compounds from the ZINC database. The virtual screening process, coupled with rigorous filtering and prioritization, which yielded a selection of potential ChAT inhibitors. The top five candidates, CPD1, CPD2, CPD3, CPD4 and CPD5 identified through molecular dynamics simulations and MMPBSA binding free energy calculations, represent promising avenues for further exploration as potential development of diagnostic biomarker in the quest to combat AD.

In conclusion, this thesis signifies a pioneering effort in the pursuit of novel derivatives as selective inhibitors of ChAT. Our synthesis endeavors have yielded compounds of substantial yield and high purity, marked by potent activity against ChAT. In vivo pharmacokinetic studies indicated optimum parameters and good brain permeability. Moreover, traditional as well as an innovative AI-assisted virtual screening initiatives has unearthed a trove of potentially novel ChAT inhibitors, offering a glimpse into the future of AD diagnostics.

This research work represents not only a significant contribution to the field of neurodegenerative disease research but also a testament to the relentless pursuit of knowledge and solutions that drive scientific inquiry. I extend my heartfelt appreciation to my mentors, colleagues, and supporters who have accompanied me on this intellectual journey. May the insights and discoveries contained within these pages inspire further exploration, ignite new avenues of research, and ultimately contribute to the global effort to combat AD and related neurodegenerative conditions.

Date: 14/05/2025

Place: IIT (BHU)

Anurag T.K. Baidya

(Anurag TK Baidya)